Cronus Pharma Launches First FDA-Approved Bioequivalent Robenacoxib Injection for Veterinary Use
First bioequivalent to ONSIOR® (robenacoxib) Injection equips veterinarians with new, cost-effective NSAID (nonsteroidal anti-inflammatory) option for controlling postoperative pain and inflammation with certain surgical procedures in dogs and cats. EAST BRUNSWICK, N.J. — Cronus Pharma LLC, a veterinary pharmaceutical company focused on developing high-quality, cost-effective animal health products, today announced the U.S. launch of Robenacoxib […]
Financial Post
First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on .
Signal breakdown
CurrentWire ranked this story 66.5 of 100 in the snapshot this page was rendered from.
- Freshness
- 32 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (5), United States (90), First FDA-Approved Bioequivalent Robenacoxib Injection (none), Veterinary Use (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.